Table 2.
Comparison of Serologic and Histologic Features with Respect to GC Stage
| Variable | Total | Intestinal type GC | Diffuse type GC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| EGC (n=697) | AGC (n=424) | p-value | EGC (n=479) | AGC (n=169) | p-value | EGC (n=203) | AGC (n=243) | p-value | |
| H. pylori status | 0.572 | 0.797 | 0.297 | ||||||
| Negative | 98 (14.1) | 65 (15.3) | 75 (15.7) | 28 (16.6) | 21 (10.3) | 33 (13.6) | |||
| Positive | 597 (85.9) | 359 (84.7) | 402 (84.3) | 141 (83.4) | 182 (89.7) | 210 (86.4) | |||
| Pepsinogen | |||||||||
| sPGI, µg/L | 61.79±43.53 | 61.75±52.55 | 0.990 | 53.83±38.75 | 55.87±44.73 | 0.571 | 79.71±48.43 | 64.72±57.13 | 0.003* |
| sPGII, µg/L | 22.71±34.35 | 24.48±27.47 | 0.251 | 19.14±17.78 | 25.58±28.36 | 0.001* | 30.76±31.72 | 22.91±23.49 | 0.003* |
| sPGI/II ratio | 3.30±2.19 | 3.07±2.19 | 0.069 | 3.29±2.40 | 2.73±1.68 | 0.005* | 3.31±1.66 | 3.29±1.83 | 0.896 |
| OLGA† | <0.001* | <0.001* | <0.001* | ||||||
| Low risk | 355 (85.3) | 190 (79.8) | 242 (84.9) | 71 (71.7) | 102 (85.0) | 111 (86.0) | |||
| High risk | 61 (14.7) | 48 (20.2) | 43 (15.1) | 28 (28.3) | 18 (15.0) | 18 (14.0) | |||
| OLGIM† | <0.001* | <0.001* | <0.001* | ||||||
| Low risk | 533 (77.4) | 304 (74.5) | 348 (73.3) | 101 (62.0) | 172 (86.4) | 193 (82.8) | |||
| High risk | 156 (22.6) | 104 (25.5) | 127 (26.7) | 62 (38.0) | 27 (13.6) | 40 (17.2) | |||
Data are presented as number (%) or median±SD.
GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer; H. pylori, Helicobacter pylori; sPG, serum pepsinogen; OLGA, operative link on gastric atrophy; OLGIM, operative link on gastric intestinal metaplasia.
*
Asterisk indicates statistical significance; †Subjects after excluding non-applicable specimens in the atrophy and intestinal metaplasia groups due to problems such as improper fixation, inaccurate orientation, and dense inflammation.